Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
暂无分享,去创建一个
J. Trigo | D. Aguiar-Bujanda | J. Oramas | J. Fírvida | A. L. Ortega-Granados | R. Gordo | J. Fuentes | R. Galán | J. de Castro | A. Artal-Cortes